NCT03408236View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

December 13, 2018

Study Completion Date

June 7, 2019

Conditions
Crow's Feet Lines
Interventions
DRUG

Botulinum toxin type A

Experimental

DRUG

Botulinum toxin type A

Active Comparator

Trial Locations (1)

Unknown

Hugel, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT03408236 - Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines | Biotech Hunter | Biotech Hunter